Keyword search (4,163 papers available)

"Rosa-Neto P" Authored Publications:

Title Authors PubMed ID
1 Associations between brain and cognitive resilience, tau load and extent in Alzheimer's disease Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; 41512332
PERFORM
2 Alzheimer s Imaging Consortium Mitchell SW; Chan T; Trudel L; Hosseini SA; Macedo AC; Gonçalves MP; Rahmouni N; Hall BJ; Socualaya KMQ; Therriault J; Servaes S; Bezgin G; Zheng Y; Aumont E; Wang YT; Arias JF; Real APB; Jia WL; Hopewell R; Hsiao C; Soucy JP; Vitali P; Pascoal TA; Rosa-Neto P; 41433447
PERFORM
3 Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H; 41358624
PSYCHOLOGY
4 The PREVENT-AD cohort: Accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Fajardo Valdez A; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterbe 41020412
SOH
5 The PREVENT-AD cohort: accelerating Alzheimer s disease research and treatment in Canada and beyond Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda-Brown C; Tardif CL; Gauthier CJ; Descoteaux M; Dadar M; Vachon-Presseau É; Baril AA; Ducharme S; Montembeault M; Geddes MR; Soucy JP; Rajah N; Laforce R; Bocti C; Davatzikos C; Bellec L; Rosa-Neto P; Baillet S; Evans AC; Collins DL; Chakravarty MM; Blennow K; Zetterberg H; S 40778177
PSYCHOLOGY
6 Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; 39893139
CONCORDIA
7 Alzheimer's Imaging Consortium Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; 39782975
CONCORDIA
8 Biomarkers Soucy JP; Belasso CJ; Cai Z; Bezgin G; Stevenson J; Rahmouni N; Tissot C; Lussier FZ; Rosa-Neto P; Rivaz HJ; Benali H; 39784152
CONCORDIA
9 Basic Science and Pathogenesis Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H; 39751468
CONCORDIA
10 Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; 39636028
HKAP
11 Neuromodulatory subcortical nucleus integrity is associated with white matter microstructure, tauopathy and APOE status Wearn A; Tremblay SA; Tardif CL; Leppert IR; Gauthier CJ; Baracchini G; Hughes C; Hewan P; Tremblay-Mercier J; Rosa-Neto P; Poirier J; Villeneuve S; Schmitz TW; Turner GR; Spreng RN; 38830849
SOH
12 Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; 38221806
CSBN
13 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
14 Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H; 37920382
PERFORM
15 Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; 35420022
PERFORM
16 Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA; 34628195
PERFORM
17 CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; 33532543
PERFORM
18 Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E 33401137
PERFORM
19 Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants 32725777
PERFORM
20 Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, 32582834
PERFORM
21 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C 32559027
CSBN
22 Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P 31530809
PERFORM
23 Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E 31507359
PERFORM
24 Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging. DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E 27578494
PERFORM
25 Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA 28894304
PERFORM
26 Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative 29396637
PERFORM

 

Title:Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation
Authors:Scala SGKang MSCox SMLRosa-Neto PMassarweh GLeyton M
Link:https://pubmed.ncbi.nlm.nih.gov/38221806/
DOI:10.1111/adb.13358
Publication:Addiction biology
Keywords:PETmGlu5 receptorssubstance use
PMID:38221806 Category: Date Added:2024-01-15
Dept Affiliation: CSBN
1 Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada.
2 Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
3 Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
4 Department of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
5 McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada.
6 Department of Psychology, McGill University, Montreal, Quebec, Canada.
7 Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Quebec, Canada.

Description:

Addictions are thought to be fostered by the emergence of poorly regulated mesocorticolimbic responses to drug-related cues. The development and persistence of these responses might be promoted by altered glutamate transmission, including changes to type 5 metabotropic glutamate receptors (mGluR5s). Unknown, however, is when these changes arise and whether the mGluR5 and mesocorticolimbic alterations are related. To investigate, non-dependent cocaine polydrug users and cocaine-naïve healthy controls underwent a positron emission tomography scan (15 cocaine users and 14 healthy controls) with [11 C]ABP688, and a functional magnetic resonance imaging scan (15/group) while watching videos depicting activities with and without cocaine use. For some drug videos, participants were instructed to use a cognitive strategy to lower craving. Both groups exhibited drug cue-induced mesocorticolimbic activations and these were larger in the cocaine polydrug users than healthy controls during the session's second half. During the cognitive regulation trials, the cocaine users' corticostriatal responses were reduced. [11 C]ABP688 binding was unaltered in cocaine users, relative to healthy controls, but post hoc analyses found reductions in those with 75 or more lifetime cocaine use sessions. Finally, among cocaine users (n = 12), individual differences in prefrontal [11 C]ABP688 binding were associated with midbrain and limbic region activations during the regulation trials. Together, these preliminary findings raise the possibility that (i) recreational polydrug cocaine users show biased brain processes towards cocaine-related cues and (ii) repeated cocaine use can lower cortical mGluR5 levels, diminishing the ability to regulate drug cue responses. These alterations might promote susceptibility to addiction and identify early intervention targets.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University